Markets:

Overview

News

Currencies

International

Treasuries

Phathom Pharmaceuticals, Inc. - Common Stock (NQ:PHAT)

14.96 +0.60 (+4.14%)

Streaming Delayed Price Updated: 3:15 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Phathom Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 12, 2022

Via Benzinga

Phathom Pharmaceuticals: Q1 Earnings Insights ↗

May 10, 2022

Phathom Pharmaceuticals (NASDAQ:PHAT) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

90 Biggest Movers From Yesterday ↗

May 10, 2022

Gainers

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

January 18, 2022

Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever (NYSE:UL) was the largest firm by market cap to set a...

Via Benzinga

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗

May 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗

May 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business ↗

August 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc...

Via Benzinga

The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗

May 02, 2022

Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates ↗

May 01, 2022

The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a...

Via Benzinga

Phathom Pharma's Vonoprazan Commercial Preparation Update At Needham Healthcare Conference ↗

April 13, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

March 15, 2022

During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

February 09, 2022

Gainers Bone Biologics (NASDAQ:BBLG) shar...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

January 12, 2022

On Wednesday, 41 stocks made new 52-week lows. Facts of Interest About Today's 52-Week Lows: Biogen (NASDAQ:BIIB) was the biggest company by market cap to set a...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 28, 2021

Gainers Medigus (NASDAQ:MDGS) shares moved upwards by 12.04% to $1.62 during Thursday's pre-market session. The market value of their outstanding shares is at $38.6...

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

January 07, 2022

Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana (NYSE:HUM) was the biggest company on a market cap...

Via Benzinga

30 Stocks Moving in Thursday's Pre-Market Session ↗

October 28, 2021

Gainers InflaRx N.V. (NASDAQ: IFRX) rose 47.9% to $4.23 in pre-market trading. Raymond James upgraded InflaRx from Outperform to Strong Buy and announced a $14 price target....

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 27, 2021

Gainers Nurix Therapeutics (NASDAQ:NRIX) stock moved upwards by 15.4% to $33.42 during Wednesday's regular session. Trading volume for Nurix Therapeutics's stock...

Via Benzinga

46 Biggest Movers From Yesterday ↗

October 19, 2021

Gainers Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial...

Via Benzinga

64 Biggest Movers From Yesterday ↗

October 28, 2021

Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 83.4% to close at $5.30. Siyata Mobile released their Q2 earnings on an October 15th call that included CEO Marc...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 18, 2021

Gainers Dermata Therapeutics (NASDAQ:DRMA

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 18, 2021

Gainers Progenity (NASDAQ:PROG) shares increased by 33.17% to $2.85 during Monday's regular session. As of 12:30 EST, Progenity's stock is trading at a volume of...

Via Benzinga

34 Stocks Moving In Monday's Mid-Day Session ↗

October 18, 2021

Gainers Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare....

Via Benzinga

Mid-Morning Market Update: Markets Mostly Lower; Albertsons Tops Q2 Estimates ↗

October 18, 2021

Following the market opening Monday, the Dow traded down 0.32% to 35,182.99 while the NASDAQ rose 0.12% to 14,915.84. The S&P also fell, dropping 0.06% to 4,468.81. The U.S....

Via Benzinga

Topics Stocks

Phathom's Vonoprazan Non-Inferior To Proton Pump Inhibitor For Esophagitis Inflammation ↗

October 18, 2021

Phathom Pharmaceuticals Inc (NASDAQ: PHAT) has announced data from the PHALCON-EE Phase 3 trial evaluating vonoprazan versus lansoprazole for erosive esophagitis (...

Via Benzinga

Phathom Pharma's Vonoprazan Inhibits Gastric Acid In Healthy Volunteers ↗

September 27, 2021

Phathom Pharmaceuticals Inc (NASDAQ: PHAT) has reported results from the VONO-103 Phase 1 trial of vonoprazan in healthy subjects. The trial evaluated the effects of...

Via Benzinga

Director Of Phathom Pharmaceuticals Makes $587 Thousand Sale ↗

September 24, 2021

David A Socks, Director at Phathom Pharmaceuticals (NASDAQ:PHAT), made a large insider sell on September 22, according to a new SEC filing. What Happened: A Form 4 filing from the...

Via Benzinga

Topics Regulatory Compliance

Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2021 ↗

May 12, 2021

Upgrades Craig-Hallum upgraded the previous rating for ShotSpotter Inc (NASDAQ:SSTI) from Hold to Buy. For the first quarter, ShotSpotter had an EPS of $0.02, compared to...

Via Benzinga

The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs ↗

April 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Phathom Pharmaceuticals, Inc. - Common Stock (NQ:PHAT)

All News about Phathom Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today